EHA 2021 | Practical considerations for CAR-T therapy in lymphoma
Ulrich Jäger
• 18 Jun 2021
Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, discusses practical considerations for the use of chimeric antigen receptor (CAR) T-cell therapies in lymphoma. Prof. Jäger talks on the findings of a study of 500 patients receiving CAR-T therapy in the real-world setting, highlighting the importance of careful patient selection whilst also commenting on benefits seen in patients who may not have appeared optimal candidates. Prof. Jäger also discusses the safety and toxicity of CAR-T therapies, in particular for tisagenlecleucel (tisa-cel). This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
